On behalf of SITC, we are pleased to announce the publication of a new manuscript titled, “A SITC Vision: Adapting Clinical Trials to Accelerate Drug Development in Cancer Immunotherapy” available now in the Journal for ImmunoTherapy of Cancer (JITC).
This manuscript is the second in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer, which outlines the current state of the field, elevates the most pressing challenges, and proposes the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. This series will serve as an update to the landmark editorial published by SITC leaders in 2011, “Defining the critical hurdles in cancer immunotherapy.”
In the 13 years since that publication, cancer immunotherapy has grown exponentially and completely transformed cancer care. As we enter the next era of cancer immunotherapy, SITC leadership recognized the importance of understanding the complex and evolving landscape of both old and new challenges that might hinder the next wave of immuno-oncology approvals or further progress in the field. To support and galvanize the field, an international, multidisciplinary group of the cancer immunotherapy experts from academic, pharmaceutical, biotechnology, patient advocacy, and regulatory institutions was convened to redefine the most pressing challenges today and high-impact opportunities to overcome them.
Areas of Opportunity in Cancer Immunotherapy
This second manuscript in the series explores strategies and tools for the next wave of IO drug development and opportunities to harness the power of both biomarkers and the neoadjuvant setting earlier in drug development as a mechanism to accelerate the field. The manuscript offers additional discussion on innovations in clinical, manufacturing, and regulatory science for the effective delivery of novel IO agents to patients and providers.
More information on this special series can be found here.